Dysregulation of melatonin metabolism in chronic renal insufficiency: Role of erythropoietin-deficiency anemia

Kidney International

Volumn 50, Issue 2, 1996, Pages 653-656

  Vaziri, Nostratola D ^a,b   Oveisi, Fariba ^a   Reyes, Gabriel A ^a   Zhou, Xin Jin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; MELATONIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CHRONIC KIDNEY FAILURE; CIRCADIAN RHYTHM; CONTROLLED STUDY; CREATININE CLEARANCE; HEMATOCRIT; HORMONE BLOOD LEVEL; HORMONE METABOLISM; INTRAPERITONEAL DRUG ADMINISTRATION; LIGHT DARK CYCLE; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; TISSUE LEVEL;

EID: 0029788369     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1996.361     Document Type: Article

References (45)

1. KRAUSE DK, DUBOCOVICH ML: Regulatory sites in the melatonin system of mammals. TINS 13:464-470, 1990
2. MESS B, TRENTINI GP, RUZSAS C, DE GACTANI CF: Some endocrine effects of the pineal gland and melatonin with special reference to reproduction. Prog Brain Res 52:329-340, 1979
3. DEMAINE C, KANN HC: Modifications of the electrical activity of hypothalamic neurons by pineal indoles. Prog Brain Res 52:373-375, 1979
4. MARTIN JE, McKEEL DW, SATTLER C: Melatonin directly inhibits gonadotrophin cells. Endocrinology 110:1079-1084, 1982
5. KINSON GA, PEAT F: The influences of illumination, melatonin and pinealectomy on testicular function in the rat. Life Sci 10:259-269, 1971
6. VRIEND J: Influence of the pineal gland, melatonin and circadian rhythms on TRH content of the medial basal hypothalamus of the Syrian hamster, in The Pineal Gland: Endocrine Aspects (vol 53), edited by BROWN GM, WAINWRIGHT SD, Oxford. Pergamon Press, 1984, pp 247-250
7. KINSON GA, SINGER B, GRANT L: Adrenocortical hormone secretion at various time intervals after pinealectomy in the rat. Gen Comp Endocr 10:447-449, 1968
8. GUPTA D: The pineal gland in relation to growth and development in children. J Neural Transm (Suppl 21):217-232, 1986
9. MAESTRONI GJM, CONTI A, PIERPAOLI W: Role of pineal gland in immunity: Circadian synthesis and release of melatonin modulates the antibody response and antagonizes the immunosuppressive effect of corticosterone. J Neuroimmunol 13:19-30, 1986
10. BLASK DE: The pineal-An oncostatic gland?, in The Pineal Gland, edited by REITER RJ, New York, Raven Press, 1984, pp 253-284
11. BLASK DE, HILL SM: Effects of melatonin on cancer: Studies on MCF-7 human breast cancer cells in culture. J Neural Transm (Suppl 21):433, 1986
12. TAMARKIN L, DANFORTH D, LICHTER A, DE Moss E, COHEN M, CHABNER B, LIPPMAN M: Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer. Science 216:1003-1005, 1982
13. WEST RJ, LEONARD JV: Familial insulin resistance with pineal hyperplasia metabolic studies and the effect of hypophyscctomy. Arch Dis Child 55:619-621, 1980
14. PIERI C, MARRA M, MORONI F, MARCHASELLI F: Melatonin: A potent endogenous pcroxyl radical scavenger more effective than vitamin E. Life Sci 55(Suppl 15):PL271-PL276, 1994
15. HARDELAND R, REITER RJ, POEGGELER B, TAN DX: The significance of metabolism of the neurohormone, melatonin: Antioxidative protection and formation of bioactive substances. Neurosci Biobehav Rev 17:347-357, 1993
16. TERMAN M, TERMAN JS, COOPER TB, Lo ES, GORMAN JM, STEWART JW, MCGRATH PJ: Response of the melatonin cycle to phototherapy for seasonal affective disorder. J Neural Transm 72:147-165, 1988
17. MAURIZI CP: Why not treat melancholia with melatonin and tryptophan and treat seasonal affective disorders with bright light? Med Hypothesis 27:271-276, 1988
18. COWDEN EA, RATCLIFFE WA, RATCLIFFE JG, KENNEDY AC: Hypothalamic-pituitary function in uremia. Acta Endocrinol 98:488-495, 1981
19. LIM VS, FANG VS: Gonadal dysfunction in uremic men. Am J Med 58:655-662, 1975
20. KAPTEIN EM, QUION-VERDE H, CHOOLJIAN CJ: The thyroid in end-stage renal disease. Medicine 67:187-197, 1988
21. LIM VS, FANG VS, KATZ AI, REFETOFF S: Thyroid dysfunction in chronic renal failure. J Clin Invest 60:522-534, 1977
22. CZERNICHOW P, DAUZET MC, BROYER M, RAPPACORT R: Abnormal TSH, PRL and GH response to TSH releasing factor in chronic renal failure. J Clin Endocrinol Met 43:630-637, 1976
23. ZABETAKIS PM, KUMAR DN, GLEIM GM, GARDENSWARTZ MH, AGRAWAL M, ROBINSON AG, MICHELIS MF: Increased levels of plasma renin, aldosterone, catecholamines and vasopressin in chronic ambulatory peritoneal dialysis (CAPD) patients. Clin Nephrol 28:147-151, 1987
24. DARWISH R, ELIAS A, VAZIRI ND, PAHL MV, POWERS D, STOKLS JD: Plasma and urinary catecholamines and their metabolites in chronic renal failure. Arch Intern Med 144:69-71, 1984
25. ELIAS A, VAZIRI ND, MAKSY M: Plasma beta-endorphin and beta-lipotropin in patients with end-stage renal disease: Effect of hemodialysis. Nephron 43:173-176, 1986
26. ELIAS A, VAZIRI ND, PANDIAN MR, IYER K, ANSARI A: Gamma-aminobutyric acid and dysrcgulation of TSH secretion in uremic male rats. Nephron 46:301-304, 1987
27. ELIAS AN, VAZIRI ND, PANDIAN MR, IYER K, ANSARI A: Dopamine and TSH secretion in uremic male rats. Horm Res 27:102-108, 1987
28. ELIAS AN, VAZIRI ND, PANDIAN MR, IYER K, ANSARI MA: Endogenous opioids and TSH secretion in azotemic male rats. Neuroendocrinology 47:181-185, 1988
29. ELIAS AN, VAZIRI ND, PANDIAN MR, IYER K, ANSARI A, YAZDANI M: Gonadtropin secretion in azotemic male rats: Effect of opioid blockade. Horm Res 30:39-43, 1988
30. ELIAS AN, VAZIRI ND, PANDIAN MR, NAWABI MA, KHAMISEH G: Glucose intolerance in renal failure: Role of endogenous opioids. J Lab Clin Med 116:191-195, 1990
31. FADDA GZ, HAJJAR SM, PERNA AF, ZHOU XJ, LIPSON LG, MASSRY SG: On the mechanism of impaired insulin secretion in chronic renal failure. J Clin Invest 87:255-261, 1991
32. ROBERTS JC, KJELLSTRAND CM: Choosing death: Withdrawal from chronic dialysis without medical reason. Acta Med Scand 223:181-186, 1988
33. GOKEAKAN Z: The effectiveness of psychological counseling for long-term hemodialysis patients. Dial Transplant 20:26-29, 1991
34. KING K: Noncompliance in the chronic dialysis population. Dial Transplant 20:67-68, 1991
35. BOULTON-JONES JM, VICK R, CAMERON VR, BLACK PJ: Immune responses in uremia. Clin Nephrol 1:351-360, 1973
36. REDDY M, GOH KO, CESTERO RVM: T and B lymphocytes in patients with chronic renal disease on hemodialysis. Experimentia 8:980, 1975
37. VAZIRI ND, OVEISI F, WIERSZBIEZKI MA, SHAW V, SPORTY L: Serum melatonin and 6-sulfatoxymelatonin in end-stage renal disease: Effect of hemodialysis. Artif Organs 17:764-769, 1993
38. VILJOEN M, STEYN ME, VAN RENSBURG BWJ, REINACH SG: Melatonin in chronic renal failure. Nephron 60:138-143, 1992
39. RAMIREZ G, BITTLE PA, SANDERS H: Hypothalamo-hypophyseal thyroid and gonadal function before and after erythropoietin therapy in dialysis patients. J Clin Endocrinol Metab 74:517-524, 1992
40. KOKOT F, WIECEK A, SCHMIDT-GAYK H, MARCINKOWSKI W, GILGE U, HEIDLAND A, RUDKA R, TREMBECKI J: Function of endocrine organs in hemodialysis patients of long-term erythropoietin therapy. Artif Organs 19:428-435, 1995
41. SAGALES T, GIMENO V, PLANELLA MJ, RAGUER N, BARTOLOME J: Effects of rHuEPO on Q-EEG and event-related potentials in chronic renal failure. Kidney Int 44:1109-1115, 1993
42. NISSENSON AR: Epoetin and cognitive function. Am J Kid Dis 20:21-24, 1992
43. VAZIRI ND, ZHOU XJ, SMITH J, OVEISI F, BALDWIN K, PURDY RE: In vivo and in vitro pressor effects of erythropoietin in rats. Am J Physiol (Renal Fluid Electrol Physiol) 38:F838-F845, 1995
44. TIEFENAUER LX, ANDERS RY: Prevention of bridge binding, effects in haptenic immunoassay system exemplified by an iodinated radioimmunoassay for melatonin. J Immunol Meth 74:293-298, 1984
45. FOLLY PB, CAIRNCROSS K, FOLDES A: Pineal indoles: Significance and measurement. Neurosci Biobehav Rev 10:273-293, 1986